For a person with epilepsy, pregnancy does not make seizure control less important; it makes treatment decisions more complex. A medicine that has kept someone seizure-free may carry reproductive risks. Changing it may reduce fetal exposure to a higher-risk drug, but it can also destabilize seizure control, and pregnancy itself can change how some antiseizure medicines are processed.
That is what makes epilepsy in pregnancy a balancing problem rather than a simple medication-safety question.
To understand how clinicians approach that balance, MDForLives surveyed neurology and epilepsy healthcare professionals across the USA, UK, Canada, Italy, France and Germany. The detailed findings are available in the MDForLives Epilepsy in Pregnancy: Balancing Seizure Control and Medication Safety Insight Report.
Plan the medication before pregnancy starts
The most useful time to review antiseizure medications in pregnancy may be before pregnancy begins. In the MDForLives research, 73.4% of respondents said planned pregnancy prompted an antiseizure medication review.
Preconception planning gives clinicians time to revisit seizure history, epilepsy type, current medication and reproductive plans before pregnancy narrows the options, and to discuss folic acid and contraception where relevant. The finding does not mean every patient planning pregnancy needs a medication change: some may be best served by continuing an effective regimen, while others may benefit from a lower-risk option or dose optimization before conception. The practical goal is to enter pregnancy with the safest effective regimen that can reasonably preserve seizure control.
Seizure control is part of safety too
Medication choice becomes more complex when fetal risk is considered. In the survey, 40.5% of clinicians selected valproate teratogenicity risk as the factor most influencing preconception medication selection, while the same proportion selected fetal neurodevelopmental risk.
Guidance referenced in the MDForLives report recommends avoiding valproate in people who may become pregnant when clinically feasible and considering lower-risk alternatives when appropriate for the epilepsy syndrome. But a lower reproductive-risk profile is not enough on its own: a replacement treatment must still provide adequate seizure control, because uncontrolled convulsive seizures can also create maternal and fetal risk. That is why epilepsy treatment during pregnancy is not best framed as seizure control versus fetal safety; the objective is to protect both.
Understanding seizure patterns is an important part of epilepsy management, including events that occur during sleep. Explore how epileptic seizures while sleeping are diagnosed and treated.
Unplanned pregnancy makes the decision urgent
The same decisions become harder when pregnancy begins before the medication plan has been reviewed. Clinicians in the MDForLives survey identified unplanned pregnancy as the leading complication in reproductive epilepsy management.
The deeper issue is time. Fetal medication exposure may already have occurred, while changing an effective regimen can introduce another concern in breakthrough seizures. A decision that could be considered gradually before conception may therefore need greater caution once pregnancy is established. For clinicians, reproductive planning should be part of ongoing epilepsy care rather than something that waits for pregnancy to trigger the conversation.
Pregnancy can change exposure even at the same dose
Choosing an appropriate seizure medication during pregnancy is only the beginning, because pregnancy can alter drug clearance and distribution. A dose that produced stable exposure before conception may not produce the same concentration later. In the MDForLives survey, 46.8% of respondents identified falling serum antiseizure medication levels as the pregnancy-related change most likely to alter medication management.
For selected medicines and patients, preconception baseline concentrations and repeat monitoring can provide useful context. But serum levels should not be interpreted alone; they need to be considered alongside seizure history, adherence and previous effective exposure. The takeaway is that monitoring is most useful when it helps identify meaningful change before it appears only as loss of seizure control.

Dose adjustment needs a clinical picture, not one number
A lower drug concentration does not automatically mean the dose should be increased. In the survey, 62.3% of clinicians identified seizure recurrence as a factor guiding medication adjustment during pregnancy, with fetal-safety concerns and serum ASM concentrations also commonly considered.
Together, these findings describe a three-part decision: clinical status, medication exposure, and fetal safety. A patient who remains seizure-stable may need a different response from someone developing breakthrough seizures, even if both show lower serum concentrations.
Neurological treatment decisions often require clinicians to balance diagnostic evidence, patient symptoms and individual clinical circumstances. Explore what really drives decisions in modern neurology.
The practical aim is not to chase a population reference range, but to preserve effective exposure while avoiding unnecessary escalation. In other words, antiseizure medications in pregnancy require active, individualized management rather than automatic continuation or automatic dose adjustment.
Delivery creates another medication transition
The medication-management problem does not end when pregnancy does. If an antiseizure medication dose was increased during pregnancy, continuing that pregnancy-adjusted dose unchanged after delivery may produce a different exposure as physiology returns toward baseline. In the MDForLives research, 32.9% of respondents selected restoring the pre-pregnancy dose as the approach that best guides postpartum management, while another 32.9% selected checking postpartum serum levels.
The two responses point to the same principle: postpartum medication management should be planned rather than assumed. Dose review, serum concentrations where appropriate, seizure control and sleep disruption may all matter during this transition. For clinicians, the postpartum plan belongs in the pregnancy conversation, not only in the first visit after delivery.
Closing perspective: protect both sides of the equation
Epilepsy in pregnancy is not simply a question of minimizing medication exposure, and it is not a question of maintaining seizure control at any cost. It is a sequence of linked decisions that begins before conception and continues after delivery.
Preconception review creates time to assess reproductive risk. Pregnancy may change drug exposure, making monitoring and clinical review important. Dose decisions need to consider seizure control, medication levels and fetal safety together. After delivery, the regimen may need another deliberate transition.
The most useful principle is straightforward: choose the safest effective regimen, monitor whether pregnancy changes its effectiveness, and plan the postpartum transition before it becomes urgent. That is how medication safety and seizure control can support each other rather than compete.
Frequently Asked Questions
Is epilepsy treatment during pregnancy always changing?
No. Treatment should be individualized. Some patients may continue an effective regimen, while others may benefit from preconception medication review, a lower-risk medicine or dose optimization.
Which antiseizure medications are considered in pregnancy?
Medication choice depends on the patient’s epilepsy and previous response. Guidance referenced in the MDForLives report recommends considering options such as lamotrigine, levetiracetam or oxcarbazepine when clinically appropriate, while avoiding valproate where feasible because of its reproductive risks.
Should seizure medication during pregnancy be stopped if pregnancy is confirmed?
Antiseizure medication should not be stopped abruptly without specialist assessment. Sudden loss of seizure control can create significant maternal and fetal risk. Any change during an established pregnancy requires careful assessment of both seizure and medication-related risk.
Why can antiseizure medication levels fall during pregnancy?
Pregnancy can change drug clearance and distribution, reducing concentrations of some antiseizure medicines despite an unchanged dose. Monitoring may be useful for selected medicines and patients when interpreted alongside seizure control and clinical history.
Does antiseizure medication need to be reviewed after delivery?
Yes, particularly when doses were adjusted during pregnancy. As pregnancy-related pharmacokinetic changes resolve, clinicians may need to review the dose, serum concentrations where appropriate, and seizure control rather than automatically continuing the pregnancy regimen.


